AbCellera Biologics
ABCL· Manufacturing· Fiscal year ends in December
Carl L.G. Hansen, Ph.D. is the CEO of AbCellera Biologics and was paid $6.3M in FY2025 (Dec), down 24%.
Executives4
See all- 1Carl L.G. Hansen, Ph.D.Chief Executive OfficerFY2025
- 2Andrew BoothChief Financial OfficerFY2025
- 3Tryn StimartChief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy OfficerFY2025
- 4Véronique Lecault, Ph.D.Chief Technology OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allAbCellera Biologics paid its 4 named executives $14.3M in total in FY2025 (Dec). CEO Carl L.G. Hansen, Ph.D. was paid $6.3M of that.
| Name | |||
|---|---|---|---|
| Carl L.G. Hansen, Ph.D.Chief Executive Officer | |||
| Andrew BoothChief Financial Officer | |||
| Tryn StimartChief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy Officer | |||
| Véronique Lecault, Ph.D.Chief Technology Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers20
See allThe FY2025 (Dec) proxy of AbCellera Biologics names 20 peer companies for pay. Among AbCellera Biologics and these peers, CEO pay was 8th highest of 9 and total shareholder return was the lowest of 9.
8th highest of 9in AbCellera Biologics and its pay peers, FY2025 (Dec) by CEO pay:
9th highest of 9in AbCellera Biologics and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 29, 2026 | FY2025 |
| Annual report | 10-K | Feb 24, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 29, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 29, 2024 | FY2023 |
| Annual report | 10-K | Feb 20, 2024 | FY2023 |
